Quicklinks▼
Careers
Citrix Storefront
Contact
Departments & Centers
Donate
Emergency Preparedness
Find Employees
LSU Health New Orleans
Intranet
Moodle
myLSUHSC
Office 365
Office 365 Mail
Patient Care
Remote VPN
Self Service
LSU Health New OrleansDISCOVER LSU BRAIN TUMOR PROGRAM
In addition to multidisciplinary excellence in clinical care, the LSU Brain Tumor Program strives to provide patients with access to clinical trials of promising treatments in addition to standard treatments.
The LSU Brain Tumor Program is affiliated with the LSU Stanley S Scott Cancer Center, and is a proud member of the Gulf South Minority/Underserved (GS-MU) NCORP. The NCI sponsored Community Oncology Research Program (NCORP) provides access to multicenter collaborative oncology trials for residents of New Orleans, as well as those across the state of Louisiana, and in those in neighboring Gulf South states, who are diagnosed with cancer.
Clinical studies help bridge research and patient care by evaluating therapies, drugs and diagnostic tools to drive discoveries into clinical practice.
Newly Diagnosed and Recurrent Glioblastoma
GBM AGILE
An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM
People with either a new diagnosis of glioblastoma or with evidence that their tumor has returned or started to grow again after their initial treatment may be eligible. This trial is studying multiple treatment options, with the results of molecular testing on the tumor determining which arm(s) a person would qualify for. There are several unique and exciting aspects of this trial. It’s designed to “adaptively randomize” people to treatment options based on how effective the treatment appears to be based on information being collected as the trial is carried out. This should allow for a higher likelihood that patients are assigned to an arm that will turn out to be effective for their tumor. The design also promises to bring drugs from multiple pharmaceutical companies into a single trial with the goal of getting effective drugs approved sooner and moving on from ineffective drugs more quickly. In addition to the experimental treatment options, some people enrolled to this trial may be randomized to arms that include standard of care treatment options.
Newly Diagnosed Glioblastoma
Wake Forest WF-1801
A Single Arm, Pilot Study of Ramipril for Preventing Radiation – Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
People with a new diagnosis of glioblastoma and who have yet to get treatment may be eligible. This trial is investigating whether a common blood pressure drug is helpful to prevent or diminish side effects of radiation on memory and concentration when it is combined with the standard treatment for glioblastoma.
Recurrent Glioblastoma
CG01-GBM
Standard Chemotherapy versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Glioblastoma Multiforme (GBM)
People who were previously diagnosed with glioblastoma and now have evidence that their tumor has come back or has started to grow again and who would otherwise be getting surgery or a biopsy as part of their treatment may be eligible. At the time of surgery, a piece of tumor is sent to a lab where testing is done to determine the sensitivity of the tumor to various chemotherapy regimens. People are then randomized to one of two arms and their treatment is then either determined by the treating doctor or is directed by the results of the sensitivity testing. Enrollment to this trial would need to take place BEFORE surgery occurs, and surgery would need to take place under the care of one of the surgeons in the LSU Neurosurgery Department to be eligible.
Recurrent Anaplastic Astrocytoma
OT-15-001 (STELLAR)
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After irradiation and Adjuvant Temozolomide Chemotherapy
People who were previously diagnosed with an anaplastic astrocytoma (WHO grade III astrocytoma) and now have evidence that their tumor has returned or has started to grow again without evidence that it has progressed to a glioblastoma (WHO grade IV astrocytoma) may be eligible to participate. This study is comparing treatment with CCNU (aka lomustine or Gleostine), which is a standard of care treatment, to treatment with CCNU and an investigational drug called eflornithine to see if the investigational approach is better. Eligibility can be based on MRI imaging characteristics of tumor progression and may not require a second surgery depending on the clinical circumstances.
Oligodendroglioma
N0577 (CODEL)
Phase III Intergroup study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q co-deleted Anaplastic Glioma or Low-Grade Glioma
People who are diagnosed with an oligodendroglioma (either WHO grade II or III) and who haven’t yet undergone treatment may be eligible. This study is comparing two common treatment regimens, radiation followed by PCV (Procarbazine, CCNU, and vincristine) or radiation with temozolomide during and after radiation, to see which is better and/or less toxic. While both treatment approaches are common for various types of brain tumors, this is the first time these treatment regimens will be compared head to head to see which is better.
Brain Metastases
Alliance A071701
Genomically-Guided Treatment Trial in Brain Metastases. This is a prospective Phase 2 study evaluating the efficacy of a CDK, P13K or NTRK/ROS1 inhibitor in patients with progressive brain metastases harboring the alterations predicting sensitivity to each of these inhibitors.
People with any solid cancer (such as lung cancer) with known brain metastasis(es) who have previously undergone surgery and have available tissue from both systemic cancer and brain metastasis(es) who now have evidence of either progression of a brain metastasis(es) or a new brain metastasis(es) may be eligible. All tumors samples will be submitted to the Alliance biorepository for tracking and processing and will undergo central biomarker testing to look for the presence of specific mutations in both systemic tumor samples and brain metastases that predict sensitivity to one or more of the mutation specific treatments under study. Patients harboring these mutations and who meet eligibility criteria will be enrolled to study the effectiveness of these treatments in treating brain metastases.
Gliomas and other brain tumors
Southeastern Study of Cancer and The Environment
People who were recently diagnosed with certain types of brain tumors including meningiomas and gliomas of any grade may be eligible for this study. Some tumors included are, Glioblastoma, low-grade glioma, anaplastic glioma, oligodendroglioma and ependymoma. Participating involves answering a questionnaire and allowing researchers access to your medical information to determine if people in the Southeast who are diagnosed with one of these tumors might have any factors in their history that may have put them at risk.
* Clicking the “NCT-” number hyperlink will take you to the official National Clinical Trials database listing of the clinical trial on clinicaltrials.gov.